Search alternatives:
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
age increased » rate increased (Expand Search), use increased (Expand Search), large increases (Expand Search)
ai large » a large (Expand Search), via large (Expand Search), _ large (Expand Search)
i large » _ large (Expand Search), a large (Expand Search), via large (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
a age » _ age (Expand Search), g age (Expand Search), 9 age (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
age increased » rate increased (Expand Search), use increased (Expand Search), large increases (Expand Search)
ai large » a large (Expand Search), via large (Expand Search), _ large (Expand Search)
i large » _ large (Expand Search), a large (Expand Search), via large (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
a age » _ age (Expand Search), g age (Expand Search), 9 age (Expand Search)
-
161
Table_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.xls
Published 2020“…However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.</p>Methods<p>We investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). …”
-
162
The effect of aging in primary human dermal fibroblasts
Published 2019“…A large number of biological mechanisms, such as decreasing of protein synthesis of extracellular matrix or increasing of degradation, are known to be altered through skin aging. …”
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
Table 1_Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.docx
Published 2025“…Introduction<p>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL), with 20-40% of patients experiencing poor outcomes despite advancements in treatment. …”
-
171
-
172
-
173
Table4_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
174
Table3_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
175
Table6_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
176
Table2_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
177
Table5_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
178
-
179
-
180